Associate Project Manager: Process Development & Tech Transfer

Milestone for Biotechnology Made in Germany: Miltenyi Biotec invests in expansion of production facility in Cologne. (C)[Translate to English:] Cologne, Germany, Mai 13, 2026. Bergisch Gladbach-based Miltenyi Biotec B.V. & Co. KG currently provides innovative cell and gene therapies to around 6,000 people worldwide each year. Demand continues to rise, and with it, the need for production capacity. For this reason, the globally active biotechnology and biomedicine company, which has about 4,600 staff members worldwide, invests in the expansion of its site in Cologne. Miltenyi Biotec is completely renovating a building complex that was formerly used for pharmaceutical manufacturing and packing processes. It will be used for manufacturing reagents for clinical applications, under the company name of Cologne Clinical Products Miltenyi Biotec (CPMB). The project recently reached a key milestone when the process technology equipment was installed. The expert team of Drees & Sommer SE supports Miltenyi Biotec in this future-oriented transformation. The consulting firm focuses on providing advice in the areas of construction, real estate and infrastructure. Since its establishment in Bergisch Gladbach's Moitzfeld district in 1989, Miltenyi Biotec B.V. & Co. KG has developed into a leading player in Germany's biotechnology sector. The company is committed to research into innovative cell therapies and is considered a pioneer, particularly in cancer immunotherapy and the treatment of tumor diseases using cell therapies such as CAR-T cells. Martin Meyer, Head of Clinical Production at Miltenyi comments: "Today, we have a portfolio with over 19,000 products, spanning from automated production systems, through to analysis and diagnosis tools, and clinical reagents." However, as he points out, demand is often higher than supply. "This is why, we completely renovate and modernize the entire building complex in Cologne. Our modernized facility will give us more space for the production of clinical reagents, based on the highest standards of quality," he continues. A Challenging Brownfield Site - Efficient Repurposing for Sterile Production Processes The existing premises offer a floor area of around 12,000 square meters, of which 5,000 square meters on the ground floor are used for the production of clinical reagents. In addition, construction includes personnel airlocks in the basement and two floors for technical use on the first and second floor, as well as approximately 430 square meters of office space. "Brownfield projects such as this one pose a particular challenge for us because we have to redesign existing spaces to meet the requirements of their new use. At first, we analyze what can be preserved from the existing infrastructure and used in future as well," explains Harald Gräfe, manager and expert for pharmaceutical buildings at Drees & Sommer." In Cologne, for example, parts of the building shell, the structural framework and selected cleanroom ceilings will remain in place. Anything that can no longer be used will be replaced or supplemented with state-of-the-art technology within the existing building structure. This includes sophisticated cleanroom conditions for sterile production processes and a digital infrastructure that connects and monitors all processes. The manager adds: "We also integrate the strict regulatory requirements of Good Manufacturing Practice, or GMP, into the building design and technology right from the start," GMP comprises a broad set of regulations that ensures clinical reagents are manufactured under controlled, reproducible and verifiable conditions. These include defined cleanroom categories, controlled flows of materials and people, hygienic surfaces, and the obligation of seamless documentation. Drees & Sommer's project team provides several services, including project management, technical project controls, digital GA audit as commissioning controls, and building information modeling (BIM) management. BIM planning connects all planning, construction and operational processes that can be represented in a centralized digital building model, known as the digital twin of the building. "Structured BIM management enables a trackable and quality-assured project handling. This increases the transparency across teams and helps maintain process efficiency at all stages of the project," explains Sebastian Sebold, specialist for BIM solutions at Drees & Sommer. Innovative Energy Concept for Climate-Friendly Production Besides the technical tools, energy supply plays a major role in the future viability of the site. The new approach to energy focuses on a decentralized structure rather than the previous centralized supply system. Harald Gräfe points out: "In future, high-temperature and ultra-high-temperature heat pumps will be used at this location. These can provide both process heat up to two hundred degrees and steam, with high energy efficiency." Energy consumption and the emission of carbon dioxide will be decisively lower than before. "This delivers climate-friendly production on an industrial scale," he adds. The Future of Biotechnology Made in Germany For Miltenyi Biotec, the expansion of the Cologne facility is a strategic step toward global competitive strength: "Germany has the chance to position itself as a leading biotechnology nation in the coming years, next to the US and Chinese markets. Through the CPMB project, we are doing our part to get closer to this goal, making therapies 'made in Germany' available to significantly more patients worldwide, more quickly and more cost-effectively," says Martin Meyer. Commissioning of Miltenyi Biotec's fully modernized production facility is scheduled for end-2026.

Slingshot Biosciences appoints Jim Snook as Senior Vice President, Global Sales. Mar 05, 2026, 09:30 ET Industry veteran brings extensive life sciences commercial leadership experience from Biotechne, Miltenyi Biotec, and Adaptive Biotechnologies EMERYVILLE, Calif., March 5, 2026 /PRNewswire/ - Slingshot Biosciences, the pioneer of synthetic cell mimic technology for flow cytometry controls, today announced the appointment of Jim Snook as Senior Vice President, Global Sales. In this role, Snook will lead the company's rapidly growing global sales organization, including management of Business Development Vice Presidents, Inside Sales and Distribution Managers, and Field Application Scientists. Snook brings more than two decades of executive sales leadership experience in the life sciences industry to Slingshot Biosciences. Most recently, he served as Vice President, Commercial for the Protein Sciences business unit at Bio-Techne, where he led the transformation of the sales organization to capture share and enable growth. Prior to Bio-Techne, Snook led the Americas commercial team at Miltenyi Biotec, growing the organization into the market leader in cell and gene therapy manufacturing and analytical solutions. "Jim's appointment marks a pivotal moment for Slingshot Biosciences as we accelerate our global growth," said Glenn Bilawsky, Chief Executive Officer of Slingshot Biosciences. "His proven track record of building high-performing sales organizations and driving substantial revenue growth at leading life sciences companies makes him the ideal leader to take our commercial efforts to the next level. Jim's deep understanding of the flow cytometry and cell therapy markets, combined with his expertise in scaling sales operations, will be instrumental in expanding our reach and serving our customers worldwide." Snook's appointment comes as Slingshot Biosciences experiences rapid adoption of its synthetic cell mimic platform among pharmaceutical companies, biotechnology firms, clinical diagnostics laboratories, and academic research institutions. His leadership will be critical in capitalizing on the growing demand for reproducible, high-quality biomarker controls in cell-based assay development and cell therapy manufacturing. "I'm thrilled to join Slingshot Biosciences at such an exciting time in the company's growth," said Jim Snook. "The platform represents a genuine breakthrough in addressing many of the challenges in complex cell analysis from robust assay development through scalable deployment... Slingshot has developed an enabling solution for the flow cytometry community, and our consultative team looks forward to bringing this technology to researchers, labs and manufacturers around the globe." About Slingshot Biosciences Slingshot Biosciences is transforming cell-based assay quality and reliability by providing precise, reproducible synthetic controls that enable faster scientific breakthroughs and positive patient impact. The company's patented platform combines advanced polymer chemistry with semiconductor manufacturing precision to create synthetic cell mimics that deliver unmatched reproducibility, long-term stability, and significant cost savings compared to traditional biological controls. Slingshot Biosciences serves customers in pharmaceutical, biotechnology, clinical diagnostics, and academic research worldwide. For more information, visit www.slingshotbio.com. Media Contact: SOURCE Slingshot Biosciences